Squarepoint
FDMT icon

Squarepoint’s 4D Molecular Therapeutics FDMT Stock Holding History

Squarepoint’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$582K Sell
62,513
-9,208
-13% -$80.1K ﹤0.01% 3214
2025
Q4 		$538K Buy
71,721
+24,884
+53% +$252K ﹤0.01% 3154
2025
Q3 		$407K Sell
46,837
-6,042
-11% -$36.1K ﹤0.01% 3418
2025
Q2 		$196K Buy
+52,879
New +$186K ﹤0.01% 3984
2024
Q4 		– Sell
-50,320
Closed -$544K – 5157
2024
Q3 		$544K Sell
50,320
-59,721
-54% -$991K ﹤0.01% 3028
2024
Q2 		$2.31M Buy
110,041
+95,422
+653% +$2.39M ﹤0.01% 1945
2024
Q1 		$466K Buy
+14,619
New +$373K ﹤0.01% 3097
2023
Q4 		– Sell
-47,749
Closed -$608K – 4143
2023
Q3 		$608K Buy
47,749
+33,056
+225% +$553K ﹤0.01% 2646
2023
Q2 		$266K Sell
14,693
-46,665
-76% -$859K ﹤0.01% 3039
2023
Q1 		$1.05M Sell
61,358
-768
-1% -$14.9K ﹤0.01% 1857
2022
Q4 		$1.38M Buy
+62,126
New +$960K 0.01% 1603

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Squarepoint's FDMT Position: Q1 2026 in Review

Squarepoint reduced its 4D Molecular Therapeutics (FDMT) stake by 13% in Q1 2026, selling an estimated $80.1K and leaving 62,513 shares worth $582K. The position accounts for ﹤0.01% of the portfolio, ranked #3214.

Squarepoint first reported a position in FDMT in Q4 2022 and has held it in 11 quarters since. The position peaked at $2.31M in Q2 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Squarepoint held 62,513 shares of 4D Molecular Therapeutics worth $582K as of Q1 2026.
  • Squarepoint sold 9,208 4D Molecular Therapeutics shares in Q1 2026, an estimated $80.1K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3214 holding.
  • Squarepoint first reported a position in 4D Molecular Therapeutics in Q4 2022 and has held it in 11 quarters since.
  • Squarepoint's 4D Molecular Therapeutics position peaked at $2.31M in Q2 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.